|
Targacept Backpedals on TC-6987 After Data Analysis Error
Targacept’s asthma candidate TC-6987 met only one of its co-primary endpoints in a Phase II study, the company revealed April 10, placing the asthma indication on shakier ground than previously reported.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives